Risk factors for disease progression in idiopathic pulmonary fibrosis. Issue 1 (14th October 2019)

• Record Type: Journal Article
• Authors: Raghu, Ganesh; Ley, Brett; Brown, Kevin K; Cottin, Vincent; Gibson, Kevin F; Kaner, Robert J; Lederer, David J; Noble, Paul W; Song, Jin Woo; Wells, Athol U; Whelan, Timothy P; Lynch, David A; Humphries, Stephen M; Moreau, Emmanuel; Goodman, Krista; Patterson, Scott D; Smith, Victoria; Gong, Qi; Sundy, John S; O'Riordan, Thomas G; Martinez, Fernando J
• Is Part Of: Thorax. Volume 75:Issue 1(2020)
• Page Start: 78
• Page End: 80
• Publication Date: 2019-10-14
• Subjects: idiopathic pulmonary fibrosis; Chest -- Diseases -- Periodicals; Thorax; Chest -- Diseases; Periodicals; Periodicals; 617.54
• DOI: 10.1136/thoraxjnl-2019-213620
• Languages: English
• ISSNs: 0040-6376

Abstract

Abstract : In this retrospective study of a randomised trial of simtuzumab in idiopathic pulmonary fibrosis (IPF), prodromal decline in forced vital capacity (FVC) was significantly associated with increased risk of mortality, respiratory and all-cause hospitalisations, and categorical disease progression. Predictive modelling of progression-free survival event risk was used to assess the effect of population enrichment for patients at risk of rapid progression of IPF; C-index values were 0.64 (death), 0.69 (disease progression), and 0.72 (adjudicated respiratory hospitalisation) and 0.76 (all-cause hospitalisation). Predictive modelling may be a useful tool for improving efficiency of clinical trials with categorical end points.